Lannett launches 2 generics through recently inked deals
Lannett is bringing two generics to market through recent agreements with partners.
The company on Tuesday announced an agreement with a strategic alliance partner that will make it the exclusive U.S. distributor of generic Syprine (trientine hydrochloride). The generic of Bausch Health Companies' drug will be available in 250-mg dosage strength. The product had a market size of roughly $140 million for the year ended November 2018.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product for which it will receive a percentage of net profits. Other financial terms were not disclosed.
"We expect to commence shipping trientine soon and believe we will be one of only a few suppliers," Lannett CEO Tim Crew said. "We are focused and remain on track to launch a sizeable number of products in the near term. These include internally developed as well as in-licensed products. Our ongoing goal is to add products to our growing portfolio, increasing and further diversifying our revenue base."
The new agreement came as Lannett kicks off marketing of its generic Comtan (entacapone IR) tablets. The generic of Novartis' drug is available in 200-mg dosage strength. Lannett previously had been enlisted as the exclusive distributor of the generic Comtan by Sunshine Lake, the U.S. subsidiary of HEC Pharm Group of China. Lannett's generic Comtan had a market size of roughly $23 million for the year ended November 2018.
For both generics, the company said it expects actual generic market values to be lower than the reported market sizes.
The company on Tuesday announced an agreement with a strategic alliance partner that will make it the exclusive U.S. distributor of generic Syprine (trientine hydrochloride). The generic of Bausch Health Companies' drug will be available in 250-mg dosage strength. The product had a market size of roughly $140 million for the year ended November 2018.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product for which it will receive a percentage of net profits. Other financial terms were not disclosed.
"We expect to commence shipping trientine soon and believe we will be one of only a few suppliers," Lannett CEO Tim Crew said. "We are focused and remain on track to launch a sizeable number of products in the near term. These include internally developed as well as in-licensed products. Our ongoing goal is to add products to our growing portfolio, increasing and further diversifying our revenue base."
The new agreement came as Lannett kicks off marketing of its generic Comtan (entacapone IR) tablets. The generic of Novartis' drug is available in 200-mg dosage strength. Lannett previously had been enlisted as the exclusive distributor of the generic Comtan by Sunshine Lake, the U.S. subsidiary of HEC Pharm Group of China. Lannett's generic Comtan had a market size of roughly $23 million for the year ended November 2018.
For both generics, the company said it expects actual generic market values to be lower than the reported market sizes.